Precision Immunology Through Deeper, Single Cell Profiling
Recorded On: 02/06/2017
|Three trends have dominated biomedical research over the last decade. The first, the NIH Roadmap's Single Cell Analysis Program, was founded on the principle that cells are extremely heterogenous, and that this heterogeneity is important in health and disease. For this reason, cells must be characterized individually, rather than by insensitive and misleading analysis of bulk cell populations. This trend renewed appreciation for cellular heterogeneity, and incited a revolution of new technologies that could comprehensively analyze single cells (the second trend, deep profiling). Finally, a third biomedical research trend was sparked by President Obama's Precision Medicine Initiative, which aims to define genomic and proteomic differences between patient groups, and use this information to inform treatment decisions. |
In this talk, I will discuss my work at the intersection of these three trends, and demonstrate the value of new technologies for comprehensive and complete cellular analysis. I will provide examples of how deep knowledge about immune responses can be attained, using examples drawn from our recent work in HIV vaccine settings, immunotherapy, and fundamental immunology. This talk will highlight our work developing 30 parameter flow cytometry, single cell RNA sequencing, and new bioinformatic tools and include some discussion of how microfluidics and nanotechnologies can fit into a pipeline that includes the above technologies.
Pratip K. Chattopadhyay, Ph.D.
Precision Medicine Incubator, Vaccine Research Center, NIH
Dr. Chattopadhyay is a Johns Hopkins and NIH-trained researcher, with expertise developing single-cell technologies to study cellular immunology. Specifically, his work involves: 1) development or optimization of new tools for highly multiplexed analysis of single cells, including: 30 parameter flow cytometry, Fluidigm BioMark (single cell analysis of 96 gene transcripts simultaneously), and widely used assays for quantifying antigen-specific cells; 2) studies of the overlap between antigen-specific T-cell traits; 3) application of novel single-cell technologies to identify T-cell profiles that predict disease outcome or vaccine efficacy in infectious disease, cancer, and immunotherapy. Dr. Chattopadhyay’s papers have been cited 3783 times (h-index = 28), and his work appears on the Faculty of 1000, BioLegend, Invitrogen, and BD BioSciences websites. He has been recognized with NIH Special Service and Merit Awards, as a Visiting Professor (Duke University Center for AIDS Research), and as an International Society for the Advancement of Cytometry Scholar.